Research

Hormonal

Real-world users of semaglutide (Wegovy) for weight management rarely follow recommended dose titration protocols, with the majority stopping at or below 1.0 mg rather than reaching the target 2.4 mg dose evaluated in clinical trials.

If you are using Wegovy, know that most people do not reach the maximum 2.4 mg dose. Many stop at 1.0 mg due to side effects or cost. This does not mean the drug isn't working for you, but it may mean your weight loss potential is lower than what is seen in clinical trials. Discuss your dose with your provider to see if escalation is appropriate for your tolerance and financial situation.

GoodQualifiesHIGH confidence
Only 13% reached the maximum dose of 2.4 mg by their 5th prescription... Overall, 10% followed the treatment guidelines of increasing the dose every four weeks... 33-48% continued with the 1.0 mg dosage from the fourth prescription onwards.
Louise Ladebo et al. · Diabetes Care · 2024

Why this rating

Large population-based cohort study (n=110,748) using national registries, minimizing selection bias, though it lacks direct anthropometric outcome data.

Source

Real-World Use of Semaglutide for Weight Management: Patient Characteristics and Dose Titration—A Danish Cohort Study

Louise Ladebo et al. · Diabetes Care · 2024

DOI 10.2337/dc24-1082

cohort · n=110748Cited 34×
Read the paper
DOI resolved against Crossref · corpus check 2026-06-10

This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →